Advertisement

Additional cytogenetic changes and previous genotoxic exposure predict unfavorable prognosis in myelodysplastic syndromes and acute myeloid leukemia with der(1;7)(q10;p10)

      Abstract

      We analyzed 23 patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) showing a der(1;7)(q10;p10) [hereafter der(1;7)] to identify the exact predictive factor of this cytogenetic change. Eight (34.8%) patients, including six with MDS and two with AML patients, had a previous history of genotoxic exposure, especially radiation and/or antimetabolites. Patients with der(1;7) consisted of three groups: one third of patients had a previous history of genotoxic agents, one third had additional cytogenetic changes at the time of MDS/AML diagnosis without previous exposure history, and the remaining one third had neither a previous exposure history nor additional cytogenetic changes. The current study demonstrated that the poor outcome of MDS/AML with der(1;7) is caused by the high frequency of associated risk factors (i.e., previous history of genotoxic exposure, the presence of additional cytogenetic changes, or both). Identification of prognostic disadvantage might be required for applying the appropriate strategy in managing MDS/AML patients with rare der(1;7) abnormality.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Cancer Genetics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Pedersen-Bjergaard J.
        • Philip P.
        • Larsen S.O.
        • Jensen G.
        • Byrsting K.
        Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia.
        Blood. 1990; 76: 1083-1091
        • Mecucci C.
        Molecular features of primary MDS with cytogenetic changes.
        Leuk Res. 1998; 22: 293-302
        • Pedersen-Bjergaard J.
        • Timshel S.
        • Andersen M.K.
        • Andersen A.S.T.
        • Philip P.
        Cytogenetically unrelated clones in therapy-related myelodysplasia and acute myeloid leukemia: experience from the Copenhagen series updated to 180 consecutive cases.
        Genes Chromosomes Cancer. 1998; 23: 337-349
        • Mhawech P.
        • Saleem A.
        Myelodysplastic syndrome: review of the cytogenetic and molecular data.
        Crit Rev Oncol Hemat. 2001; 40: 229-238
        • Block A.W.
        • Carroll A.J.
        • Hagemeijer A.
        • Micaux L.
        • van Lom K.
        • Olney H.J.
        • Baer M.R.
        Rare recurring balanced chromosome abnormalities in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop.
        Genes Chromosomes Cancer. 2002; 33: 401-412
        • LeBeau M.M.
        • Espinosa III, R.
        • Davis E.M.
        • Eisenbart J.D.
        • Larson R.A.
        • Green E.D.
        Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases.
        Blood. 1996; 88: 1930-1935
        • Mauritzson N.
        • Johansson B.
        • Rylander L.
        • Albin M.
        • Stromberg U.
        • Billstrom R.
        • Ahlgren T.
        • Mikoczy Z.
        • Mitelman F.
        • Hagmar L.
        The prognostic impact of karyotypic subgroups in myelodysplastic syndrome is strongly modified by sex.
        Br J Haematol. 2001; 113: 347-356
        • Geraedts J.P.M.
        • Ottolander G.J.
        • Den Polem J.E.
        • Muntinghe O.G.
        An identical translocation between chromosome 1 and 7 in three patients with myelofibrosis and myeloid metaplasia.
        Br J Haematol. 1980; 44: 569-575
        • Scheres J.M.J.C.
        • Hustinx T.W.J.
        • Haldrinet R.S.G.
        • Geraedts J.P.M.
        • Hagemeijer A.
        • van der Blyphilipsen M.
        Translocation 1;7 in dyshematopoiesis: possibly induced with a nonrandom geographic distribution.
        Cancer Genet Cytogenet. 1984; 12: 283-294
        • Sandberg A.A.
        • Morgan R.
        • Hecht B.K.
        • Hecht F.
        Translocation (1;7)(p11;p11): a new myeloproliferative hematology entity.
        Cancer Genet Cytogenet. 1985; 18: 199-206
        • Scheres J.M.J.C.
        • Hustinx T.W.J.
        • Geraedts J.P.M.
        • Leeksma H.W.
        • Meltzer P.S.
        Translocation 1;7 in hematologic disorders: a brief review of 22 cases.
        Cancer Genet Cytogenet. 1985; 18: 207-213
        • Horiike S.
        • Taniwaki M.
        • Misawa S.
        • Nishigaki H.
        • Okuda T.
        • Yokota S.
        • Kashima K.
        • Inazawa J.
        • Abe T.
        The unbalanced 1;7 translocation in de novo myelodysplastic syndrome and its clinical implication.
        Cancer. 1990; 65: 1350-1354
        • Pedersen B.
        • Norgaard J.M.
        • Pedersen B.B.
        • Clausen N.
        • Rasmussen I.H.
        • Thorling K.
        Many unbalanced translocations show duplication of a translocation participant. Clinical and cytogenetic implications in myeloid hematologic malignancies.
        Am J Hematol. 2000; 64: 161-169
        • Rowley J.D.
        • Olney H.J.
        International workshop on the relationship for prior therapy to balanced chromosome aberrations in therapy-related myelodysplastic syndromes and acute leukemia: overview report.
        Genes Chromosomes Cancer. 2002; 33: 331-345
        • Pedersen B.
        Survival of patients with t(1;7)(p11;p11): report of two cases and review of the literature.
        Cancer Genet Cytogenet. 1992; 60: 53-59
        • Greenberg P.
        • Cox C.
        • LeBeau M.M.
        • Fenaux P.
        • Morel P.
        • Sanz G.
        • Vallespi T.
        • Hamblin T.
        • Oscier D.
        • Ohyashiki K.
        • Toyama K.
        • Aul C.
        • Mufti G.
        • Bennett J.
        International scoring system for evaluating prognosis in myelodysplastic syndromes.
        Blood. 1997; 89: 2079-2088
        • Hsiao H.H.
        • Ito Y.
        • Sashida G.
        • Ohyashiki J.H.
        • Ohyashiki K.
        De novo appearanceof der(1;7)(q10;p10) is associated with leukemic transformation and unfavorable prognosis in essential thrombocythemia.
        Leuk Res. 2005; 29: 1247-1252
        • Vardiman J.W.
        • Harris N.L.
        • Brunning R.D.
        The World Health Organization (WHO) classification of the myeloid neoplasms.
        Blood. 2002; 100: 2292-2302
      1. Mitelman F, Johansson B, Mertens F. Mitelman database of chromosome aberrations in cancer. http://www.cgap.nci.nih.gov/Chromosomes/ Mitelman. Accessed on August 15, 2005.

        • Mecucci C.
        • Ghione F.
        • Tricot G.
        • Van den Berghe H.
        Combined trisomy 1q and monosomy 1q due to translocation 1;7 in myelodysplastic syndromes.
        Cancer Genet Cytogenet. 1985; 18: 193-197
        • Wang L.
        • Ogawa S.
        • Hangaishi A.
        • Qiao Y.
        • Hosoya N.
        • Nanya Y.
        • Ohyashiki K.
        • Mizoguchi H.
        • Hirai H.
        Molecular characterization of the recurrent unbalanced translocation der(1;7)(q10;p10).
        Blood. 2003; 102: 2597-2604
        • Pedersen-Bjergaard J.
        • Rowley J.D.
        The balanced and the unbalanced chromosome aberrations of acute leukemia may develop in different ways and may contribute differently to malignant transformation.
        Blood. 1994; 83: 2780-2786
        • Andersen M.K.
        • Pedersen-Bjergaard J.
        Increased frequency of dicentric chromosomes in therapy-related MDS and AML compared to de novo disease is significantly related to previous treatment with alkylating agents and suggests a specific susceptibility to chromosome breakage at the centromere.
        Leukemia. 2000; 14: 105-111